# Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab

> **NCT00946023** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 135 (actual)

## Conditions studied

- Lymphoma
- B-cell Lymphoma
- Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **RADIATION:** Total body irradiation
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Rituximab
- **BIOLOGICAL:** Allogeneic Bone Marrow Transplant (BMT)

## Key facts

- **NCT ID:** NCT00946023
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07
- **Primary completion:** 2013-07
- **Final completion:** 2013-07-17
- **Target enrollment:** 135 (ACTUAL)
- **Why stopped:** Funding was unavailable to complete the study as originally planned.
- **Last updated:** 2018-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00946023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00946023, "Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00946023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*